Developer docs
API playgroundTry for free, no card

Search company profiles

The SCN2A Foundation

Full company profile

uuid00hgwxn

Namestring
The SCN2A Foundation
Legal namestring
SCN2A Foundation
Company typeenum
Private
Founded yearint
2023
Descriptiontext

The SCN2A Foundation is a 501(c)(3) nonprofit patient advocacy organization co-founded in 2023 by Shannon Curry, RN, and Jason Curry after their son Jack received an SCN2A genetic diagnosis. The foundation's stated mission is to accelerate targeted therapeutic development for SCN2A-related disorders — a set of rare CNS conditions affecting brain sodium channels that sit at the intersection of untreatable epilepsy, autism, and other physical presentations. It operates from a registered office in Dover, Delaware (EIN: 92-2444780) and is privately held with no parent company, institutional investors, or subsidiaries.

The foundation's product surface consists of four core digital assets: the SCN2A Global Contact Registry (HIPAA/GDPR-compliant intake and short-form registry connecting families to research), the EMBRAVE 3 Clinical Trial Pre-Screener (a web-based eligibility questionnaire for the Praxis Precision Medicines PRAX-222 registrational trial in gain-of-function patients ages 1-18), SCN2A AI (a custom GPT built on ChatGPT that helps families interpret SCN2A variant classifications), and an educational blog covering epilepsy, mutation types, pharmacogenetics, and therapeutic approaches. The foundation does not develop proprietary therapeutic technology; instead it operates a research-coordination model that funds targeted studies, operates patient registries, and acts as a clinical trial recruitment channel.

Revenue is generated exclusively through charitable donations accepted via website, cryptocurrency, Donor Advised Funds, check, wire, and stock transfers; no products or services are sold, no pricing exists, and revenue figures are not publicly disclosed. The foundation serves four named customer segments — SCN2A patient families (primary), healthcare providers, researchers/scientists, and donors/supporters — and has assembled a network of core partnerships with Praxis Precision Medicines, Unravel Biosciences, and COMBINEDBrain, alongside supporting research resource partnerships with Simons Searchlight, SFARI Gene, Jackson Laboratory, NCBI, and GeneCards.

Short descriptiontext

The SCN2A Foundation is a 501(c)(3) nonprofit founded in 2023 that accelerates targeted therapeutic research for SCN2A-related neurological disorders. It serves SCN2A patient families, clinicians, and researchers through a global contact registry, clinical trial pre-screener, custom GPT variant-interpretation tool, and partnerships with biotech and academic organizations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAllison Park, United States
HQ citystring
Allison Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease advocacy, patient registry services, research funding coordination, genetic disorder support, clinical trial facilitation
Industry2 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code1 code
  • Voluntary Health Organizations813212
SIC code1 code
  • Services-Membership Organizations8600
Product category
Rare Disease Patient Advocacy
Revenue model1 record
1Donations and Fundraising
TypeGrants Donations
Description

The SCN2A Foundation generates revenue through charitable donations from individuals, families, and supporters. The foundation accepts donations via website, cryptocurrency, Donor Advised Funds (DAF), check, wire, and stock transfers.

scn2afoundation.org
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

The SCN2A Foundation is a 501(c)(3) nonprofit patient advocacy organization that funds and coordinates targeted research into SCN2A-related disorders, maintains a global patient contact registry, and operates clinical trial pre-screeners (notably for the Praxis Precision Medicines EMBRAVE 3 registrational study). It provides free educational resources, an AI-based variant interpretation tool (SCN2A AI), and a global community connecting affected families, clinicians, and researchers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Elsunersen ASO clinical trial shows 77% seizure reduction in children with GOF mutations
+1 more record
Product overview1 text field

The SCN2A Foundation operates as a patient advocacy nonprofit offering a suite of digital tools and resources for families affected by SCN2A-related disorders. The core offerings include: (1) SCN2A AI, a ChatGPT-based conversational AI tool for variant interpretation; (2) the EMBRAVE 3 Clinical Trial Pre-Screener, a web-based eligibility questionnaire for the ongoing PRAX-222 clinical trial; (3) the SCN2A Global Contact Registry, a patient registry connecting families with research opportunities; and (4) the SCN2A Foundation Blog, an educational resource hub with guides on epilepsy, mutation types, autism, and therapeutic approaches. These products collectively support patient education, clinical trial recruitment, and community building for a rare genetic neurological disorder affecting brain sodium channel function.

Product and service3 records
1SCN2A AI
CategoryPatient Education Tool
Description

A ChatGPT-based custom GPT tool that helps families affected by SCN2A-related disorders understand genetic variants, mutation types (gain-of-function, loss-of-function, mixed function), and variant classifications through natural language conversational interaction. It is a free patient-facing educational resource for newly diagnosed families.

2EMBRAVE 3 Clinical Trial Pre-Screener
CategoryClinical Trial Recruitment Tool
Description

A web-based eligibility questionnaire that helps families determine if their child qualifies for the EMBRAVE 3 registrational study (PRAX-222) targeting children ages 1-18 with confirmed SCN2A gain-of-function variants. The tool guides users through key eligibility criteria including age, genetic confirmation, and seizure history, and connects eligible families to study sites in the US, Italy, Germany, and UK.

3SCN2A Global Contact Registry
CategoryPatient Registry Platform
Description

A patient registry platform that connects SCN2A families globally, allowing them to find nearby families, participate in research, and contribute to the SCN2A community. Includes both an open, short-form registry and a HIPAA/GDPR-compliant detailed intake form for research participation.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-03
Description

Drug discovery collaboration focused on preclinical research for SCN2A-related disorders caused by loss-of-function mutations. The partnership evaluates therapeutic approaches in mutation-relevant laboratory models using Unravel's AI-enabled Living Molecular Twin platform. Goal is to identify strategies that may increase functional SCN2A protein in the brain and inform future therapeutic development for LOF patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership related to EMBRAVE 3 registrational study for Gain-of-Function SCN2A. Praxis is developing antisense oligonucleotide (ASO) PRAX-222 for early-onset SCN2A Developmental and Epileptic Encephalopathy (DEE). The foundation operates the pre-screener and refers eligible patients to study sites in US, Italy, Germany, and UK.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Non-profit consortium of over 60 patient advocacy groups for rare genetic neurodevelopmental disorders. SCN2A Foundation is a member organization participating in biorepository collection to provide patient samples for biomarker research. Samples stored and available to researchers globally.

Strategic tierSupportingTypeOthers
Description

Research resource partnership. Simons Searchlight is an ambitious research program creating an ever-growing database and resource network for families to contribute data and connect with research on SCN2A.

Strategic tierSupportingTypeOthers
Description

Research resource partnership. SFARI Gene is an evolving database for the autism research community centered on genes implicated in autism susceptibility, including SCN2A.

Strategic tierSupportingTypeOthers
Description

Research resource partnership. JAX provides mouse models and research tools for SCN2A research, including strain 035553 for preclinical studies.

Strategic tierSupportingTypeOthers
Description

Research resource providing access to genetic databases including Gene ID 6326 for SCN2A and ClinVar for variant classification.

Strategic tierSupportingTypeOthers
Description

Research resource providing comprehensive, searchable information on the SCN2A gene integrating data from approximately 150 web sources.

9The Human Protein Atlas
Strategic tierSupportingTypeOthers
Description

Research resource providing information on SCN2A (ENSG00000136531) protein expression and localization in human tissues.

scn2afoundation.org
10Dr. Jerry Kartzinel
Strategic tierSupportingTypeOthers
Description

Medical advisor to the foundation. Dr. Kartzinel specializes in autism and epilepsy treatment with over 30 years of experience.

11Dr. Jerry Vockley
Strategic tierSupportingTypeOthers
Description

Scientific Advisory Board member. MD, PhD, FACMG, providing genetic expertise and research guidance to foundation.

scn2afoundation.org
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Private foundation focused on CDKL5 Deficiency Disorder, a rare genetic neurodevelopmental condition. Operates a similar model of strategic therapeutic development funding, patient registry support, and academic/industry partnerships.

TypeBroad incumbent
Description

The largest US rare disease umbrella advocacy organization, providing policy, research grant programs, and patient support. Comparable as an advocacy and rare disease funding entity, though operates at much larger scale and across all rare diseases.

TypeDirect peer
Description

Family-founded nonprofit funding research for Dravet syndrome, a related sodium channelopathy (SCN1A). Highly comparable in mission, founder-driven model, and patient registry/biorepository strategy to the SCN2A Foundation.

TypeEmerging player
Description

Biotech developing antisense oligonucleotide (ASO) therapies for genetic diseases including Dravet syndrome (SCN1A), a closely adjacent modality to PRAX-222 for SCN2A. Comparable as a next-generation ASO developer targeting sodium channelopathies.

TypeDirect peer
Description

A nonprofit consortium of 60+ rare genetic neurodevelopmental disorder patient advocacy groups; the SCN2A Foundation is a member organization, making COMBINEDBrain the most structurally aligned peer, with shared biorepository infrastructure and an overlapping scientific mission.

TypeEmerging player
Description

Clinical-stage biotech developing PRAX-222 (Elsunersen) for SCN2A gain-of-function DEE, the foundation's core industry partner. Listed as a peer for comparability around SCN2A therapeutic development, though operates as a for-profit entity rather than advocacy nonprofit.

TypeEmerging player
Description

AI-enabled drug discovery company with an active preclinical collaboration with the SCN2A Foundation for LOF mutations. Comparable as a tech-enabled therapeutics developer operating at the intersection of rare disease and AI-driven discovery.

8Child Neurology Foundation
TypeBroad incumbent
Description

Established nonprofit supporting children with neurological conditions and their families. A broader incumbent in the same child-neurology advocacy space, with overlapping family-support resources but a much wider disease mandate.

TypeDirect peer
Description

Leading nonprofit dedicated to funding epilepsy research and supporting patients/families. Comparable in grantmaking model, scientific advisory structure, and patient-education focus, though broader in scope than the SCN2A Foundation.

TypeDirect peer
Description

Advocacy and support organization for Developmental and Epileptic Encephalopathies (DEEs), the same disease category as SCN2A-related DEE. Comparable mission, family community focus, and clinical trial navigation support.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

The SCN2A Foundation

Rare Disease Patient Advocacyscn2afoundation.org

The SCN2A Foundation is a 501(c)(3) nonprofit founded in 2023 that accelerates targeted therapeutic research for SCN2A-related neurological disorders. It serves SCN2A patient families, clinicians, and researchers through a global contact registry, clinical trial pre-screener, custom GPT variant-interpretation tool, and partnerships with biotech and academic organizations.

What The SCN2A Foundation does

The SCN2A Foundation is a 501(c)(3) nonprofit patient advocacy organization co-founded in 2023 by Shannon Curry, RN, and Jason Curry after their son Jack received an SCN2A genetic diagnosis. The foundation's stated mission is to accelerate targeted therapeutic development for SCN2A-related disorders — a set of rare CNS conditions affecting brain sodium channels that sit at the intersection of untreatable epilepsy, autism, and other physical presentations. It operates from a registered office in Dover, Delaware (EIN: 92-2444780) and is privately held with no parent company, institutional investors, or subsidiaries.

The foundation's product surface consists of four core digital assets: the SCN2A Global Contact Registry (HIPAA/GDPR-compliant intake and short-form registry connecting families to research), the EMBRAVE 3 Clinical Trial Pre-Screener (a web-based eligibility questionnaire for the Praxis Precision Medicines PRAX-222 registrational trial in gain-of-function patients ages 1-18), SCN2A AI (a custom GPT built on ChatGPT that helps families interpret SCN2A variant classifications), and an educational blog covering epilepsy, mutation types, pharmacogenetics, and therapeutic approaches. The foundation does not develop proprietary therapeutic technology; instead it operates a research-coordination model that funds targeted studies, operates patient registries, and acts as a clinical trial recruitment channel.

Revenue is generated exclusively through charitable donations accepted via website, cryptocurrency, Donor Advised Funds, check, wire, and stock transfers; no products or services are sold, no pricing exists, and revenue figures are not publicly disclosed. The foundation serves four named customer segments — SCN2A patient families (primary), healthcare providers, researchers/scientists, and donors/supporters — and has assembled a network of core partnerships with Praxis Precision Medicines, Unravel Biosciences, and COMBINEDBrain, alongside supporting research resource partnerships with Simons Searchlight, SFARI Gene, Jackson Laboratory, NCBI, and GeneCards.

The SCN2A Foundation firmographics

Firmographics
Name
The SCN2A Foundation
Legal name
SCN2A Foundation
Website
https://scn2afoundation.org
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
The SCN2A Foundation is a 501(c)(3) nonprofit founded in 2023 that accelerates targeted therapeutic research for SCN2A-related neurological disorders. It serves SCN2A patient families, clinicians, and researchers through a global contact registry, clinical trial pre-screener, custom GPT variant-interpretation tool, and partnerships with biotech and academic organizations.
Ownership category
akta.pro rank

The SCN2A Foundation industry classification

Industry
Product category
Rare Disease Patient Advocacy
NAICS
Voluntary Health Organizations (813212)
SIC
Services-Membership Organizations (8600)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Rare disease advocacy
  • Patient registry services
  • Research funding coordination
  • Genetic disorder support
  • Clinical trial facilitation

Where The SCN2A Foundation is headquartered

Location

Headquarters

HQ city
Allison Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

The SCN2A Foundation business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. Donations and Fundraising: The SCN2A Foundation generates revenue through charitable donations from individuals, families, and supporters. The foundation accepts donations via website, cryptocurrency, Donor Advised Funds (DAF), check, wire, and stock transfers.

Distribution channels4 records

Marketing channels8 records

The SCN2A Foundation product offering

Product offering

Core offering

The SCN2A Foundation is a 501(c)(3) nonprofit patient advocacy organization that funds and coordinates targeted research into SCN2A-related disorders, maintains a global patient contact registry, and operates clinical trial pre-screeners (notably for the Praxis Precision Medicines EMBRAVE 3 registrational study). It provides free educational resources, an AI-based variant interpretation tool (SCN2A AI), and a global community connecting affected families, clinicians, and researchers.

Product overview

The SCN2A Foundation operates as a patient advocacy nonprofit offering a suite of digital tools and resources for families affected by SCN2A-related disorders. The core offerings include: (1) SCN2A AI, a ChatGPT-based conversational AI tool for variant interpretation; (2) the EMBRAVE 3 Clinical Trial Pre-Screener, a web-based eligibility questionnaire for the ongoing PRAX-222 clinical trial; (3) the SCN2A Global Contact Registry, a patient registry connecting families with research opportunities; and (4) the SCN2A Foundation Blog, an educational resource hub with guides on epilepsy, mutation types, autism, and therapeutic approaches. These products collectively support patient education, clinical trial recruitment, and community building for a rare genetic neurological disorder affecting brain sodium channel function.

Differentiator

Problem solved

Functional benefit

Products and services

  • SCN2A AI A ChatGPT-based custom GPT tool that helps families affected by SCN2A-related disorders understand genetic variants, mutation types (gain-of-function, loss-of-function, mixed function), and variant classifications through natural language conversational interaction. It is a free patient-facing educational resource for newly diagnosed families.
  • EMBRAVE 3 Clinical Trial Pre-Screener A web-based eligibility questionnaire that helps families determine if their child qualifies for the EMBRAVE 3 registrational study (PRAX-222) targeting children ages 1-18 with confirmed SCN2A gain-of-function variants. The tool guides users through key eligibility criteria including age, genetic confirmation, and seizure history, and connects eligible families to study sites in the US, Italy, Germany, and UK.
  • SCN2A Global Contact Registry A patient registry platform that connects SCN2A families globally, allowing them to find nearby families, participate in research, and contribute to the SCN2A community. Includes both an open, short-form registry and a HIPAA/GDPR-compliant detailed intake form for research participation.

Quantifiable outcome

  • Elsunersen ASO clinical trial shows 77% seizure reduction in children with GOF mutations
  • +1 more outcomes

Companies that use The SCN2A Foundation

Customer profile

Segments4 records

Ideal customer profiles3 records

The SCN2A Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

The SCN2A Foundation partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and supporting.

  • Unravel Biosciences, Inc.coreStrategic or Co-development Partner · 3 February 2026Drug discovery collaboration focused on preclinical research for SCN2A-related disorders caused by loss-of-function mutations. The partnership evaluates therapeutic approaches in mutation-relevant laboratory models using Unravel's AI-enabled Living Molecular Twin platform. Goal is to identify strategies that may increase functional SCN2A protein in the brain and inform future therapeutic development for LOF patients.
  • Praxis Precision MedicinescoreStrategic or Co-development PartnerPartnership related to EMBRAVE 3 registrational study for Gain-of-Function SCN2A. Praxis is developing antisense oligonucleotide (ASO) PRAX-222 for early-onset SCN2A Developmental and Epileptic Encephalopathy (DEE). The foundation operates the pre-screener and refers eligible patients to study sites in US, Italy, Germany, and UK.
  • COMBINEDBraincoreStrategic or Co-development PartnerNon-profit consortium of over 60 patient advocacy groups for rare genetic neurodevelopmental disorders. SCN2A Foundation is a member organization participating in biorepository collection to provide patient samples for biomarker research. Samples stored and available to researchers globally.
  • Simons SearchlightsupportingOthersResearch resource partnership. Simons Searchlight is an ambitious research program creating an ever-growing database and resource network for families to contribute data and connect with research on SCN2A.
  • SFARI Gene (Simons Foundation)supportingOthersResearch resource partnership. SFARI Gene is an evolving database for the autism research community centered on genes implicated in autism susceptibility, including SCN2A.
  • The Jackson LaboratorysupportingOthersResearch resource partnership. JAX provides mouse models and research tools for SCN2A research, including strain 035553 for preclinical studies.
  • NCBI (National Center for Biotechnology Information)supportingOthersResearch resource providing access to genetic databases including Gene ID 6326 for SCN2A and ClinVar for variant classification.
  • GeneCardssupportingOthersResearch resource providing comprehensive, searchable information on the SCN2A gene integrating data from approximately 150 web sources.
  • The Human Protein AtlassupportingOthersResearch resource providing information on SCN2A (ENSG00000136531) protein expression and localization in human tissues.
  • Dr. Jerry KartzinelsupportingOthersMedical advisor to the foundation. Dr. Kartzinel specializes in autism and epilepsy treatment with over 30 years of experience.
  • Dr. Jerry VockleysupportingOthersScientific Advisory Board member. MD, PhD, FACMG, providing genetic expertise and research guidance to foundation.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

The SCN2A Foundation competitors and assessment

Company assessment

Direct peers

  • Loulou Foundation: Private foundation focused on CDKL5 Deficiency Disorder, a rare genetic neurodevelopmental condition. Operates a similar model of strategic therapeutic development funding, patient registry support, and academic/industry partnerships.
  • Dravet Syndrome Foundation: Family-founded nonprofit funding research for Dravet syndrome, a related sodium channelopathy (SCN1A). Highly comparable in mission, founder-driven model, and patient registry/biorepository strategy to the SCN2A Foundation.
  • COMBINEDBrain: A nonprofit consortium of 60+ rare genetic neurodevelopmental disorder patient advocacy groups; the SCN2A Foundation is a member organization, making COMBINEDBrain the most structurally aligned peer, with shared biorepository infrastructure and an overlapping scientific mission.
  • CURE Epilepsy: Leading nonprofit dedicated to funding epilepsy research and supporting patients/families. Comparable in grantmaking model, scientific advisory structure, and patient-education focus, though broader in scope than the SCN2A Foundation.
  • DEE-P Connections: Advocacy and support organization for Developmental and Epileptic Encephalopathies (DEEs), the same disease category as SCN2A-related DEE. Comparable mission, family community focus, and clinical trial navigation support.

Broad incumbents

  • National Organization for Rare Disorders (NORD): The largest US rare disease umbrella advocacy organization, providing policy, research grant programs, and patient support. Comparable as an advocacy and rare disease funding entity, though operates at much larger scale and across all rare diseases.
  • Child Neurology Foundation: Established nonprofit supporting children with neurological conditions and their families. A broader incumbent in the same child-neurology advocacy space, with overlapping family-support resources but a much wider disease mandate.

Emerging players

  • Stoke Therapeutics: Biotech developing antisense oligonucleotide (ASO) therapies for genetic diseases including Dravet syndrome (SCN1A), a closely adjacent modality to PRAX-222 for SCN2A. Comparable as a next-generation ASO developer targeting sodium channelopathies.
  • Praxis Precision Medicines: Clinical-stage biotech developing PRAX-222 (Elsunersen) for SCN2A gain-of-function DEE, the foundation's core industry partner. Listed as a peer for comparability around SCN2A therapeutic development, though operates as a for-profit entity rather than advocacy nonprofit.
  • Unravel Biosciences: AI-enabled drug discovery company with an active preclinical collaboration with the SCN2A Foundation for LOF mutations. Comparable as a tech-enabled therapeutics developer operating at the intersection of rare disease and AI-driven discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

The SCN2A Foundation social profiles

Digital presence

The SCN2A Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

The SCN2A Foundation leadership team

Management profile

Number of profiles

Profiles8 records

The SCN2A Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

The SCN2A Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The SCN2A Foundation

What does The SCN2A Foundation do?

The SCN2A Foundation is a 501(c)(3) nonprofit patient advocacy organization that funds and coordinates targeted research into SCN2A-related disorders, maintains a global patient contact registry, and operates clinical trial pre-screeners (notably for the Praxis Precision Medicines EMBRAVE 3 registrational study). It provides free educational resources, an AI-based variant interpretation tool (SCN2A AI), and a global community connecting affected families, clinicians, and researchers.

Is The SCN2A Foundation a public or private company?

The SCN2A Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was The SCN2A Foundation founded?

The SCN2A Foundation was founded in 2023. It employs 1 to 10 people.

Where is The SCN2A Foundation based?

The SCN2A Foundation is headquartered in Allison Park, United States, in the North America region.

How does The SCN2A Foundation make money?

One revenue line is on record: donations and Fundraising.

Who are The SCN2A Foundation's main competitors?

Direct peers on record are Loulou Foundation, Dravet Syndrome Foundation, COMBINEDBrain, CURE Epilepsy and DEE-P Connections. Broad incumbents are National Organization for Rare Disorders (NORD) and Child Neurology Foundation. Emerging players are Stoke Therapeutics, Praxis Precision Medicines and Unravel Biosciences.

Does The SCN2A Foundation have an API?

No public API is recorded for The SCN2A Foundation.

What industry is The SCN2A Foundation in?

The SCN2A Foundation's product category is Rare Disease Patient Advocacy. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 813212 and its SIC code is 8600.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales